The Damage Control Strategy for the Treatment of Perforated Diverticulitis of the Sigmoid Colon With Diffuse Peritonitis
Launched by STÄDTISCHES KLINIKUM MÜNCHEN GMBH · Jan 5, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding the best way to treat perforated diverticulitis, a condition where a part of the colon becomes inflamed and develops holes, leading to serious complications like widespread abdominal infection (peritonitis). The trial is looking at a specific approach called the "damage control strategy," which involves two stages of surgery. In the first stage, doctors will perform a limited removal of the affected section of the colon and temporarily close the abdomen. In the second stage, which happens a couple of days later, doctors will revisit the patient to either reconstruct the colon or take further necessary actions based on the patient's condition.
Anyone who has undergone surgery for perforated diverticulitis with generalized peritonitis might be eligible to participate in this study. Participants will have their data collected and compared to those treated with other standard techniques. This research aims to see if the damage control strategy can help reduce the need for a permanent stoma (a surgical opening in the abdomen) after surgery. If you or someone you know is considering participation, it’s important to discuss this with a healthcare provider to understand the potential risks and benefits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients who were operated for perforated diverticulitis with generalized peritonitis
- Exclusion Criteria:
- • incomplete data sets
About Städtisches Klinikum München Gmbh
Städtisches Klinikum München GmbH is a leading municipal hospital group in Munich, Germany, dedicated to delivering high-quality healthcare services and advancing medical research. With a focus on patient-centered care, the institution operates multiple specialized clinics and departments, employing state-of-the-art technology and evidence-based practices. As a clinical trial sponsor, Städtisches Klinikum München GmbH emphasizes innovation and collaboration, facilitating rigorous research initiatives aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Their commitment to ethical standards and regulatory compliance ensures the integrity and reliability of clinical research, contributing to the advancement of medical science and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials